Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in budd-chiari syndrome and their impact on thrombotic complications post Liver Transplantation

Etiology, Management, and Outcome of the Budd-Chiari Syndrome

(2013) Sarwa Darwish Murad   ANNALS OF INTERNAL MEDICINE

Results of liver transplantation in the treatment of Budd-Chiari syndrome

(2013) Marek Krawczyk   Annals of Transplantation

The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis

(2011) J. H. Smalberg et al.   BLOOD

Long-Term Follow-Up of Liver Transplantation for Budd-Chiari Syndrome With Antithrombotic Therapy Based on the Etiology

(2011) Srinath Chinnakotla et al.   TRANSPLANTATION

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

(2010) A. E. Smith et al.   BLOOD

Identification of MPL W515L/K Mutations in Patients with Primary Myelofibrosis and Essential Thrombocythaemia by Allele-Specific Polymerase Chain Reaction

(2009) Sarah Daly et al.   ACTA HAEMATOLOGICA

Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome

(2009) Azim M. Mohamedali et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

(2009) A Tefferi et al.   LEUKEMIA

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden

(2008) O. Landgren et al.   BLOOD

Disease anticipation in familial myeloproliferative neoplasms

(2008) E. Rumi et al.   BLOOD

Thrombosis and anticoagulation in liver disease

(2008) Dominique Charles Valla   HEPATOLOGY

Vascular disorders of the liver

(2008) Laurie D. DeLeve et al.   HEPATOLOGY

Genetic complexity of myeloproliferative neoplasms

(2008) R Kralovics   LEUKEMIA